trending Market Intelligence /marketintelligence/en/news-insights/trending/OLXW8YolHaBhsk1zem_6Hg2 content esgSubNav
In This List

Roche's cobas Zika virus test gets US FDA approval

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Roche's cobas Zika virus test gets US FDA approval

Roche Holding AG secured the U.S. Food and Drug Administration's approval for the cobas Zika test.

Cobas is the first commercially available test for the detection of the Zika virus RNA in samples of human plasma intended for use in screening blood donations.

Roche deployed the cobas Zika test in April 2016 under the FDA's investigational new drug application protocol to screen blood donations collected in Puerto Rico.